Stockreport

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

AptarGroup, Inc.  (ATR) 
Last aptargroup, inc. earnings: 4/30 05:04 pm Check Earnings Report
US:NYSE Investor Relations: investors.aptar.com
PDF Novel treatment for PSVT developed with Milestone Pharmaceuticals CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and cons [Read more]